NOVARTIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 92.73 CHF | -0.47% |
|
+0.76% | +9.26% |
| 01:20pm | NOVARTIS AG : JP Morgan remains Neutral | ZD |
| 12:54pm | NOVARTIS AG : Buy rating from Goldman Sachs | ZD |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows:
- oncology (29.9%);
- immunology (17.2%);
- cardiovascular, renal and metabolic diseases (14.1%);
- neuroscience (8.9%).
The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products.
At the end of 2023, Novartis AG had 33 production sites worldwide.
Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
103.1
USD
Average target price
110
USD
Spread / Average Target
+6.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.26% | 210B | |
| +41.91% | 739B | |
| +32.34% | 598B | |
| -5.93% | 353B | |
| +17.41% | 318B | |
| +3.30% | 285B | |
| +16.47% | 240B | |
| -5.07% | 206B | |
| +5.93% | 164B | |
| +1.53% | 162B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Novartis’ Scemblix Gets Third US FDA Breakthrough Therapy Designation
